TCRs In Personalized Oncology With BlueSphere Bio's Keir Loiacono
Business Of Biotech
00:00
The Noise in the Oncology Industry
There haven't been a whole lot of terrific data readouts. You know, you also have to measure expectations on what your data is going to be. I'm always impressed when I see people go after indications that nobody's ever heard of before even though it's commercially risky. Adapt immune is likely going to file their BLA this year. They could be the first TCR T cell therapy approved in solid tumors. And their lead indication will be something called synovial sarcoma.
Transcript
Play full episode
